Last reviewed · How we verify

Drug treatment with Cymbalta

Jefferson Clinic, P.C. · FDA-approved active Small molecule Quality 58/100

Drug treatment with Cymbalta is a Serotonin-norepinephrine reuptake inhibitor (SNRI) Small molecule drug developed by Jefferson Clinic, P.C.. It is currently FDA-approved. Also known as: Duloxetine Hydrochloride.

Cymbalta is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain.

Cymbalta, also known as duloxetine, is a serotonin-norepinephrine reuptake inhibitor (SNRI) primarily used to treat depression and anxiety disorders. It is also prescribed for chronic pain conditions such as diabetic neuropathy and fibromyalgia. Despite its effectiveness, Cymbalta has several side effects, including nausea, dizziness, and fatigue. The drug is not approved by the FDA for use at Jefferson Clinic, P.C., which may affect its prescription practices. Patients should be monitored closely for potential adverse reactions and interactions with other medications.

At a glance

Generic nameDrug treatment with Cymbalta
Also known asDuloxetine Hydrochloride
SponsorJefferson Clinic, P.C.
Drug classSerotonin-norepinephrine reuptake inhibitor (SNRI)
TargetSerotonin and norepinephrine transporters
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

Cymbalta works by blocking the reabsorption (reuptake) of serotonin and norepinephrine into neurons, thereby increasing their availability in the synaptic cleft.

Approved indications

Boxed warnings

Common side effects

Drug interactions

Key clinical trials

Patents

PatentExpiryType
US6127396
US6326381

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Drug treatment with Cymbalta

What is Drug treatment with Cymbalta?

Drug treatment with Cymbalta is a Serotonin-norepinephrine reuptake inhibitor (SNRI) drug developed by Jefferson Clinic, P.C..

How does Drug treatment with Cymbalta work?

Cymbalta is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain.

Who makes Drug treatment with Cymbalta?

Drug treatment with Cymbalta is developed and marketed by Jefferson Clinic, P.C. (see full Jefferson Clinic, P.C. pipeline at /company/jefferson-clinic-p-c).

Is Drug treatment with Cymbalta also known as anything else?

Drug treatment with Cymbalta is also known as Duloxetine Hydrochloride.

What drug class is Drug treatment with Cymbalta in?

Drug treatment with Cymbalta belongs to the Serotonin-norepinephrine reuptake inhibitor (SNRI) class. See all Serotonin-norepinephrine reuptake inhibitor (SNRI) drugs at /class/serotonin-norepinephrine-reuptake-inhibitor-snri.

What development phase is Drug treatment with Cymbalta in?

Drug treatment with Cymbalta is FDA-approved (marketed).

What are the side effects of Drug treatment with Cymbalta?

Common side effects of Drug treatment with Cymbalta include Nausea, Dizziness, Fatigue, Dry mouth, Constipation, Somnolence.

What does Drug treatment with Cymbalta target?

Drug treatment with Cymbalta targets Serotonin and norepinephrine transporters and is a Serotonin-norepinephrine reuptake inhibitor (SNRI).

Related